PARAISOIntravenous Prasinezumab for Early-Stage Parkinson's Disease

This clinical trial focuses on understanding how effective and safe a treatment called prasinezumab is for people who have early-stage Parkinson's disease. Parkinson's disease is a condition that affects movement and often starts with mild symptoms like a slight tremor. The study targets those who are already taking a stable dose of a common Parkinson's medication called levodopa. The goal is to see if prasinezumab can improve their symptoms or slow the progression of the disease. This research is important because finding better treatments can significantly enhance the quality of life for those living with Parkinson's. Participants in this study will receive prasinezumab through an intravenous (IV) infusion, meaning the medicine will be given directly into a vein. Some participants will receive a placebo, which is a substance with no active drug, to compare the effects. The study will monitor how prasinezumab affects the body and its safety for patients. Researchers will evaluate whether the treatment helps with Parkinson's symptoms and assess its overall safety. By comparing prasinezumab to a placebo, the study aims to provide clear insights into its potential benefits and any risks involved.